Valencia

• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting
  2023-506239-14-00 5 2022-12-13 Crohn’s Disease
• Phase III, multicenter, open-label, randomized clinical trial to evaluate efficacy of Sodium Zirconium Cyclosilicate (Lokelma) compared to s … Recruiting
  2024-517631-43-00 5 2022-12-12 Hyperkalemia in patients with chronic kidney disease
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substud … Recruiting
  2023-504484-16-00 9 2022-11-18 Multiple Myeloma (MM)
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting
  2024-510656-13-00 5 2022-11-08 Migraine
• A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, … Recruiting
  2022-500069-29-00 9 2022-11-02 Alzheimer's disease
• First-in-Human Study of RLY-2608 in Advanced Breast Cancer and Other Solid Tumors. Recruiting
  2022-500264-35-00 1 2022-10-28 Advanced solid tumor with a PIK3CA mutation in blood and/or tumor per
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch … Recruiting
  2024-512382-13-00 5 2022-10-04 Migraine (with or without aura)
• An extension study to learn if Staccato Alprazolam is safe when treating long seizures in children ≥12 years of age and adults Recruiting
  2023-508868-30-00 5 2022-09-26 Treatment of stereotypical prolonged seizure
• A study to Investigate the efficacy and safety of Depemokimab compared with placebo in Adults with Hypereosinophilic Syndrome (HES) Recruiting
  2023-510346-25-00 5 2022-09-01 Hypereosinophilic Syndrome (HES)
• A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or … Recruiting
  2023-506517-22-00 9 2022-08-31 Advanced or Metastatic Colorectal Cancer
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia Recruiting
  2023-503335-18-00 1 2022-07-29 Chronic myeloid leukemia
• An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult … Recruiting
  2024-510950-29-00 5 2022-07-21 Stereotypical prolonged seizure
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin … Recruiting
  2023-505347-38-00 9 2022-06-13 B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED) Recruiting
  2024-513412-10-00 9 2022-05-11 Anaplastic Large Cell Lymphoma (ALCL)
• EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) Recruiting
  2023-507029-40-00 5 2022-05-09 Genetic carriers of dilated cardiomyopathy causing variants
• Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Recruiting
  2023-507119-36-00 5 2022-05-09 Malignant melanoma of the skin in patients with locally advanced and f
• A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting
  2023-509743-27-00 4 2022-04-29 Systemic sclerosis associated with interstitial lung disease

Showing 793–816 of 1,853 trials